Pharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid tumours

dc.contributor.author	Cook, Natalie
dc.contributor.author	Banerji, U
dc.contributor.author	Evans, J
dc.contributor.author	Biondo, A
dc.contributor.author	Germetaki, Theodora
dc.contributor.author	Randhawa, M
dc.contributor.author	Godfrey, L
dc.contributor.author	Leslie, S
dc.contributor.author	Jeffrey, P
dc.contributor.author	Rigby, M
dc.contributor.author	Bennett, G
dc.contributor.author	Blakemore, S
dc.contributor.author	Koehler, M
dc.contributor.author	Niewiarowski, A
dc.contributor.author	Pittman, M
dc.contributor.author	Symeonides, SN
dc.date.accessioned	2019-12-09T17:23:29Z
dc.date.available	2019-12-09T17:23:29Z
dc.date.issued	2019	en
dc.identifier.citation	Cook N, Banerji U, Evans J, Biondo A, Germetaki T, Randhawa M, et al. 464P Pharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid tumours. Annals of Oncology. 2019;30(Supplement_5):174.	en
dc.identifier.doi	10.1093/annonc/mdz244.026	en
dc.identifier.uri	http://hdl.handle.net/10541/622582
dc.language.iso	en	en
dc.relation.url	https://dx.doi.org/10.1093/annonc/mdz244.026	en
dc.title	Pharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid tumours	en
dc.type	Meetings and Proceedings	en
dc.contributor.department	Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester	en
dc.identifier.journal	Annals of Oncology	en
refterms.dateFOA	2020-01-21T19:52:49Z

Name:

mdz244.026.pdf

Size:

87.92Kb

Format:

PDF

Description:

From UNPAYWALL. Conference abstract